Thrombin-activatable fibrinolysis inhibitor

You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.

Jump to: navigation, search
carboxypeptidase B2
Identifiers
Symbol CPB2
Entrez 1361
HUGO 2300
OMIM 603101
RefSeq NM_001872
UniProt Q96IY4
Other data
Locus Chr. 13 q14.11

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-525-6884

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Thrombin-activatable fibrinolysis inhibitor (TAFI), also known as plasma carboxypeptidase B2 is a recently described plasma zymogen that, when exposed to the thrombin-thrombomodulin complex, is converted by proteolysis at Arg92 to a basic carboxypeptidase (TAFIa or activated TAFI) that inhibits fibrinolysis.

TAFI is produced by the liver.

Fibrinolysis (simplified). Blue arrows denote stimulation, and red arrows inhibition.
Fibrinolysis (simplified). Blue arrows denote stimulation, and red arrows inhibition.

WikiDoc Resources for

Thrombin-activatable fibrinolysis inhibitor

Articles

Most recent articles on Thrombin-activatable fibrinolysis inhibitor

Most cited articles on Thrombin-activatable fibrinolysis inhibitor

Review articles on Thrombin-activatable fibrinolysis inhibitor

Articles on Thrombin-activatable fibrinolysis inhibitor in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Thrombin-activatable fibrinolysis inhibitor

Images of Thrombin-activatable fibrinolysis inhibitor

Photos of Thrombin-activatable fibrinolysis inhibitor

Podcasts & MP3s on Thrombin-activatable fibrinolysis inhibitor

Videos on Thrombin-activatable fibrinolysis inhibitor

Evidence Based Medicine

Cochrane Collaboration on Thrombin-activatable fibrinolysis inhibitor

Bandolier on Thrombin-activatable fibrinolysis inhibitor

TRIP on Thrombin-activatable fibrinolysis inhibitor

Clinical Trials

Ongoing Trials on Thrombin-activatable fibrinolysis inhibitor at Clinical Trials.gov

Trial results on Thrombin-activatable fibrinolysis inhibitor

Clinical Trials on Thrombin-activatable fibrinolysis inhibitor at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Thrombin-activatable fibrinolysis inhibitor

NICE Guidance on Thrombin-activatable fibrinolysis inhibitor

NHS PRODIGY Guidance

FDA on Thrombin-activatable fibrinolysis inhibitor

CDC on Thrombin-activatable fibrinolysis inhibitor

Books

Books on Thrombin-activatable fibrinolysis inhibitor

News

Thrombin-activatable fibrinolysis inhibitor in the news

Be alerted to news on Thrombin-activatable fibrinolysis inhibitor

News trends on Thrombin-activatable fibrinolysis inhibitor

Commentary

Blogs on Thrombin-activatable fibrinolysis inhibitor

Definitions

Definitions of Thrombin-activatable fibrinolysis inhibitor

Patient Resources / Community

Patient resources on Thrombin-activatable fibrinolysis inhibitor

Discussion groups on Thrombin-activatable fibrinolysis inhibitor

Patient Handouts on Thrombin-activatable fibrinolysis inhibitor

Directions to Hospitals Treating Thrombin-activatable fibrinolysis inhibitor

Risk calculators and risk factors for Thrombin-activatable fibrinolysis inhibitor

Healthcare Provider Resources

Symptoms of Thrombin-activatable fibrinolysis inhibitor

Causes & Risk Factors for Thrombin-activatable fibrinolysis inhibitor

Diagnostic studies for Thrombin-activatable fibrinolysis inhibitor

Treatment of Thrombin-activatable fibrinolysis inhibitor

Continuing Medical Education (CME)

CME Programs on Thrombin-activatable fibrinolysis inhibitor

International

Thrombin-activatable fibrinolysis inhibitor en Espanol

Thrombin-activatable fibrinolysis inhibitor en Francais

Businness

Thrombin-activatable fibrinolysis inhibitor in the Marketplace

Patents on Thrombin-activatable fibrinolysis inhibitor

Experimental / Informatics

List of terms related to Thrombin-activatable fibrinolysis inhibitor



WikiDoc Help Menu

Quick Start..

Editing basics

Advanced editing

Communicating your edits

Help Videos You Can Watch


Acknowledgement and Attribution Regarding Sources of Content

Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .

Personal tools